LIBTAYO 350 mg concentrate for solution for infusion., Vidutolimod, Vidutolimod clinical trials

A Multicenter, Open-label, Phase 2 study of Intratumoral Vidutolimod (CMP-001) in Combination with Intravenous Cemiplimab in Subjects with Selected Types of Advanced or Metastatic Cancer

This study is testing a new combination of treatments for some advanced cancers. It involves two drugs, Vidutolimod and Cemiplimab, to see how well they shrink tumours. It's a Phase II study, meaning we're looking at how safe and effective this new approach might be.